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Abstract
Background: The first reports on the pandemic influenza 2009 A/H1N1v from the USA, Mexico, and Australia indicated that
this disease was associated with a high mortality in pregnant women. The aim of this study was to describe and compare
the characteristics of severe critically ill and non-severe pregnant women with 2009 A/H1N1v-related illness in France.
Methodology/Principal Findings: A national registry wascreatedtoscreenpregnant womenwithlaboratory-confirmed 2009
A/H1N1v influenza. Three hundred and fifteen patients from 46 French hospitals were included: 40 patients were admitted to
intensive care units (severe outcomes), 111 were hospitalized in obstetric or medical wards (moderate outcomes), and 164
were outpatients (mild outcomes). The 2009 A/H1N1v influenza illness occurred during all pregnancy trimesters, but most
women (54%), notably the severe patients (70%), were in the third trimester. Among the severe patients, twenty (50%)
underwent mechanical ventilation, and eleven (28%) were treated with extracorporeal membrane oxygenation. Three women
died from A/H1N1v influenza. We found a strong association between the development of a severe outcome and both co-
existingillnesses(adjustedoddsratio[OR],5.1; 95% confidenceinterval [CI],2.2–11.8)andadelayinoseltamivirtreatmentafter
the onset of symptoms (.3 or 5 days) (adjusted OR, 4.8; 95% CI, 1.9–12.1 and 61.2, 95% CI; 14.4–261.3, respectively). Among
the 140 deliveries after 22 weeks of gestation known to date, 19 neonates (14%) were admitted to a neonatal intensive care
unit, mainly for preterm delivery, and two neonates died. None of these neonates developed 2009 A/H1N1v infection.
Conclusions: This series confirms the high incidence of complications in pregnant women infected with pandemic A/H1N1v
observed in other countries but depicts a lower overall maternal and neonatal mortality and morbidity than indicated in the
USA or Australia. Moreover, our data demonstrate the benefit of early oseltamivir treatment in this specific population.
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Introduction
Data from previous influenza pandemics have indicated that
pregnant women have a higher risk for morbidity and mortality
than do non-pregnant women [1–4]. The emergence of pandemic
influenza A/H1N1 in America and Australia in early 2009 raised
further awareness and concern in Europe [5,6]. Indeed, the first
reports from the Centers for Disease Control (CDC) [7] and
Australia [8] indicated a severe mortality and even susceptibility to
an increase in the 2009 maternal mortality ratio in the United
States [9].
The A/H1N1v pandemic was declared by the World Health
Organization on June 11
th, 2009. Alerts about the increased
mortality in pregnant women arrived from the Centers for Disease
Control (CDC) in late June [7]. The ‘‘Colle `ge National des
Gyne ´co-Obste ´triciens Franc ¸ais’’ (CNGOF), the ‘‘Socie ´te ´ Franc ¸aise
d’Anesthe ´sie Re ´animation’’ (SFAR), the ‘‘Socie ´te ´ de Pathologie
Infectieuse de Langue Franc ¸aise’’ (SPILF), and the French
Ministry of Health published guidelines in August 2009 on the
management of influenza-like illness (ILI) in pregnant women,
which were actualized in November 2009 [10–11].
Briefly, whenever a pregnant woman presented with possible
ILI, i.e., fever .37.8uC and cough or sore throat, clinicians were
asked to assess the illness severity and respiratory compromise
using physical exams and tests, such as pulse oximetry, chest X-ray
or arterial blood gases, as clinically indicated. Clinical and social
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such as preterm labor, and inability to perform self-care or to
arrange follow-up if necessary) were also assessed. In cases of
severe disease, admission to an ICU was recommended, whereas
women with mild or moderate diseases were referred to obstetric
or medical wards to exclude other possible diagnoses, to perform
an obstetric follow-up, and to initiate treatment. Women with mild
outcomes without clinical or social risk factors were treated as soon
as possible in an ambulatory setting. Antiviral treatment
(oseltamivir: 75 mg per os twice per day for 5 days) was initiated
as soon as possible after the onset of symptoms. Systematic reverse
transcriptase-polymerase chain reaction (RT-PCR) for influenza
A/H1N1 using nasal or throat swabs was performed during the
pandemic period (after December 8, it was only recommended for
severe patients), whereas it was discontinued for the general
population. Pregnant women were identified as one of the initial
target groups to receive the 2009 A/H1N1v monovalent non-
adjuvant vaccine as soon as it was available (November 20
th, 2009
in France).
Meanwhile, the National Institute for Public Health Surveil-
lance (InVS, Institut National de Veille Sanitaire) recorded all
cases of pandemic flu, either confirmed or suspected and either
severe or moderate, in the French general population until
November 2, at which time surveillance was only maintained for
the most severe patients (those requiring intensive care) [12].
Therefore, no data are available regarding the number of
pregnant or postpartum women with confirmed or suspected
H1N1 pandemic flu (hospitalized or not), except for the most
severe patients who were hospitalized in the ICU in France.
Moreover, the InVS registry could not address the identification of
risk factors involved in the development of the most severe
outcomes of flu among pregnant women or the obstetric or
neonatal outcomes.
We launched a web-based national registry (R3G, French
National Registry on Flu during Pregnancy) under the aegis of
four medical societies (CNGOF, SFAR, SRLF, and SPILF) and a
collaboration with REVA (a specific French registry on critical
care and ventilation). The aim of this registry was to record cases
of pregnant or postpartum women with laboratory-confirmed
2009 A/H1N1v virus infection from August 1
st through December
31
st, 2009 in metropolitan France to conduct a more comprehen-
sive epidemiological study.
Here, we report the main demographic characteristics, maternal
clinical course, treatment, and fetal and neonatal outcomes of
2009 A/H1N1v-infected pregnant or postpartum women with
severe outcomes (admitted to the ICU), moderate outcomes
(admitted to medical or obstetric wards), or mild outcomes (treated
as outpatients) recorded in France during this period.
Methods
Implementation of the French registry
From August 1
st through December 31
st, 2009, French
physicians were invited to report all confirmed cases of 2009
influenza A/H1N1 in pregnant or postpartum women to the web-
based French National Registry on Flu during Pregnancy. Women
who demonstrated an onset of symptoms from 48 hours to 6 weeks
after delivery were considered postpartum patients. A confirmed
case was defined as a pregnant or postpartum women that
presented with ILI and the diagnosis of 2009 influenza A/H1N1v
by specific RT-PCR. Severe patients were defined as those who
were admitted to an ICU, whereas moderate or mild patients were
those who were admitted to medical or obstetric wards or treated
as outpatients in the ambulatory setting, respectively.
The registry was based on the spontaneous reports of clinicians.
French obstetricians, anesthesiologists, and intensivists were
informed of the registry via nationwide e-mailing, specific
intervention on the website of the scientific societies, and
communication in several national meetings. A specific anony-
mous form was created on a specific and independent secured
website. The report form was standardized and included data on
demographics, past medical history, underlying medical diseases,
clinical presentation and course (for the mother and the fetus),
treatment and pregnancy outcome, if available.
We collected data on mothers’ height and weight before
pregnancy or on admission, any coexisting illnesses, gravidity,
parity, estimated date of delivery, plurality, miscarriage (defined as
fetal loss before 22 weeks of gestation), previous vaccination
against seasonal or pandemic A/H1N1v influenza, and any
medical or obstetric problems that developed during the current
pregnancy. Obesity was defined as a pre-conception BMI over
30 kg/m
2. We documented the date and time of delivery, the
occurrence of labor (either spontaneous or induced), the
indications for surgical delivery (such as maternal hypoxia or
difficult ventilation, maternal hemodynamic instability, and/or
fetal compromise), and the use of corticosteroids to induce fetal
lung maturation. For each newborn, we recorded the method of
birth (vaginal or surgical delivery), gestational age, birth weight,
whether the newborns were live born or stillborn (fetal death $22
completed weeks of gestation), Apgar score at five minutes,
admission and duration of admission to a neonatal intensive care
unit (NICU) or special care nursery, neonatal infection with 2009
A/H1N1v influenza, the occurrence of any complications, and
survival at the time of hospital discharge. Maternal and neonatal
outcomes were last updated on March 31
st, 2010. We made no
assumptions regarding missing data. Missing data were excluded
from the analysis, and all proportions were calculated as
percentages of the patients with available data.
Regarding the most severe outcomes, REVA provided the
missing data or files to be as exhaustive as possible, at least for this
group of patients. From June 1
st through December 29
th, 2009,
1015 hospitalizations for severe outcomes and 198 deaths related
to suspected- or RT-PCR-confirmed 2009 H1N1 influenza were
identified through enhanced surveillance in France by the InVS.
Among these severe outcomes and deaths, 51 were recorded as
pregnant or postpartum women [13].
Patients included in the R3G database were divided into three
groups depending on the severity of the disease and the level of
care: outpatient management for mild disease without other
medical or social risk factors; hospitalization in obstetric or
medical wards for moderate disease; and hospitalization in the
ICU for severe disease.
The present study was an epidemiological study conducted
under the aegis of four French medical societies (SFAR, CNGOF,
SRLF, SPILF). All anonymous files concerning pregnant women
with H1N1 pandemic flu were registered via the national secured
website declared to and allowed by the CNIL, which is our
National Committee on Informatics and Liberty. Data collection
was conducted as part of an urgent public health response and was
deemed exempt from review by an institutional review board. The
data were collected from all regions of France, and therefore, no
informed consent could be obtained from the patients.
Statistical analysis
Continuous variables are expressed as means 6 SD or medians
[min-max] as indicated, and categorical variables are expressed as
percentages. A comparison of the quantitative variables or
proportions across groups was performed among the 3 groups
Pregnancy & H1N1 France 2009
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exact test as appropriate. The odds ratio for developing a severe
outcome and the 95% confidence intervals (CIs) were calculated
using a conditional forward stepwise logistic regression. Only the
variables that were significant at a limit of 5% in the univariate
analysis were included in the multivariate model. A value of
p,0.05 was considered significant.
Results
From August 1
st through December 31
st, 2009, 315 pregnant or
postpartum women with confirmed 2009 A/H1N1v influenza
were included in the R3G database, and subsequent data were
collected by the French web-based registry. Among these patients,
164 (52%) were outpatients, 111 (35%) were hospitalized in
obstetric or medical wards, and 40 (13%) were hospitalized in an
ICU. Dates of symptom onset ranged from July 21
st to December
30
th, 2009 (Fig. 1), but most of the cases occurred between the 42
nd
and 49
th week of 2009.
Among the 164 outpatient women, 109 (66%) were in the first
or second trimester of pregnancy, whereas 87 of the 111
hospitalized non-severe outcome women (78%) and 27 of the 40
ICU (most severe) patients (68%) were in the third trimester of
pregnancy (Fig. 2, p,0.001). Only one ICU patient presented
with influenza symptoms two days after an elective cesarean
section following an uneventful pregnancy and was the single
postpartum case. Five patients were twin pregnancies, and none of
them had a severe outcome. Four women developed 2009
pandemic A/H1N1v influenza infection despite vaccination with
the 2009 H1N1 monovalent vaccine. Notably, these four women
had received the first injection of the vaccine less than 10 days
before the onset of flu.
The main characteristics of the patients are summarized in
Table 1. Coexisting illnesses were frequent, especially among ICU
patients (23 of 40, 58%). In contrast, pregnancy per se was the only
risk factor in 71% and 73% of the moderate and mild outcomes,
respectively (p,0.001). Asthma (9%) and obesity (12%) were the
most frequent co-morbidities among the 315 patients. Whereas
there was no significant difference in the prevalence of obesity
among the three groups, chronic respiratory disease was
significantly more frequently reported among women admitted
to the ICU (11 of 40, 28%) compared to the two other groups
(p,0.001). Among the nine ICU patients with a history of asthma,
four reported taking daily medication, which indicated severe
chronic disease. The two other ICU patients with pulmonary
disease had a restrictive syndrome (Steinert’s disease and severe
homozygous sickle cell anemia).
The most common symptoms of flu observed in this population
were fever (86%), cough (84%), muscle aches (54%), headache
(36%), and nausea/vomiting (10%), as shown in Table 2.
Shortness of breath (22%) was more frequently reported among
severe outcome ICU patients (p,0.001).
All patients who presented with severe outcomes received
antiviral treatment (oseltamivir alone or in combination with
zanamivir in two patients) (Table 2). However, the delay from
symptom onset to the initiation of antiviral treatment was more
than 48 hours in 22 of the 40 (55%) ICU patients (median time 3
Figure 1. Temporal repartition of laboratory-confirmed 2009 A/H1N1v infection among pregnant women in the French registry
according to patient status.
doi:10.1371/journal.pone.0013112.g001
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demonstrated a shorter duration to the initiation of antiviral
treatment as compared to severe outcomes: 80 and 88% of
moderate and mild outcomes, respectively, were treated less than
48 hours after onset of the illness (p,0.001).
Antibiotic therapy, mainly amoxicillin or cephalosporin com-
bined with spiramycin, was often initially co-prescribed with the
antiviral treatment in hospitalized patients (in 80% and 68% of
cases of severe or moderate disease, respectively).
Among moderate outcomes, 94 (85%) were observed and
treated in obstetric wards and 17 (15%) in medical wards. The
most common reason for admission was ILI. Sixteen hospitalized
women in the obstetric ward were admitted only for monitoring in
the absence of severe influenza symptoms or pregnancy compli-
cations, mainly during the third trimester of pregnancy. Other
patients were admitted for containment (n=25), especially during
the initial phase of the outbreak, pregnancy complications (n=21),
or decompensation of an underlying disease (n=4).
Although none of the 164 outpatients required specific obstetric
management, 11 of the 111 hospitalized non-severe (10%) and 23
of the 39 pre-partum severe patients (59%) required specific
obstetric care, as shown in Table 2. Among the hospitalized non-
severe patients, this specific obstetric care was mainly the
treatment of preterm labor (8 of the 111 patients), whereas in
the severe patients, it was mainly a cesarean section (17 of the 39
prepartum severe patients). Most of these 17 cesarean sections
were conducted for maternal hypoxemia or a worsening condition.
These cesarean sections induced preterm birth in only 13 patients:
1 at less than 29 weeks GA, 4 between 29 and 31 weeks GA, and 8
between 32 and 36 weeks GA. In contrast, there was no short-term
fetal impact of the flu pandemic in the fetuses of 260 of 264
pregnant women with moderate or mild outcomes of the disease
(98%) for whom data are available.
Forty women (13%) were hospitalized in the ICU. The mean
SAPS II and SOFA scores at admission were 28619 and 463,
respectively. These patients were slightly younger (p=0.001) than
the non-severe patients. Ten (25%) had delivered prior to ICU
admission. Most of the women (95%) were admitted to the ICU
because of a respiratory failure, as shown in Table 3. At the time of
admission, 32 of 40 women had pneumonia with an abnormal
chest radiography or chest computed tomography (80%). Ten
women (25%) presented with a documented secondary pulmonary
infection during the hospital stay (Streptococcus sp., Haemophilus
influenza, Escherichia coli, Pseudomonas aeruginosa, Aspergillus fumigatus,
cytomegalovirus), and most of them were ventilator-associated
pneumonias. Only four ICU patients had a documented bacterial
co-infection at the time of admission (Streptococcus sp. in one woman
and Streptococcus pneumoniae in three women). Cardiac dysfunction
was observed in 17 patients (43%), either associated with
respiratory failure in 16 patients or as a myocarditis without
respiratory failure in the other patient. Twenty patients (50%)
required mechanical ventilation for a median time of 13 days
[2–55]. Among the twenty patients who required mechanical
ventilation, eleven patients also required extracorporeal mem-
brane oxygenation (ECMO) for a median duration of 8 days
[4–38], among which nine survived. Five patients (13%) required
Figure 2. Gestational age at onset of symptoms according to the severity of symptoms.
doi:10.1371/journal.pone.0013112.g002
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oxygenation. The median ICU length of stay was 10 days [2–80].
Other ICU treatments are detailed in Table 3.
Three women died (8%). Two of them were in the third
trimester of pregnancy at symptom onset, and the third was in the
second trimester. All of these patients had coexisting illnesses:
obesity in one (body mass index: 31 kg/m
2), severe thrombotic
microangiopathy in another, and cardiac valvular disease (mitral
stenosis and aortic regurgitation) in the last patient. Only one of
them received antiviral medication within 48 hours after symptom
onset. The other two received oseltamivir at 8 and 9 days after first
symptom onset, likely due to poor access to care. Refractory acute
respiratory distress syndrome (ARDS, PaO2/FiO2,200) was
diagnosed in two of these three patients for whom ECMO was
unsuccessful; the third patient with acute lung injury (ALI,
200,PaO2/FiO2,300) received only protective mechanical
ventilation but died due to massive cerebral ischemia in the
context of thrombotic microangiopathy.
The multivariate analysis of risk factors for developing a severe
outcome is shown in Table 4. We found a strong association
between the development of a severe outcome from flu and both
co-existing illnesses (adjusted odds ratio [OR], 5.1; 95%
confidence interval [CI], 2.2–11.8; p,0.001) and a delay in
oseltamivir treatment after the onset of symptoms (.3 or 5 days)
(adjusted OR, 4.8; 95% CI, 1.9–12.1, p=0.001, and 61.2; 95%
CI, 14.4–261.3, p,0.001, respectively).
On March 31
st, 2009, pregnancy outcomes were known for 146
of the 231 patients with an estimated delivery date prior to March
31
st (63%). Most of the outpatients and non-ICU hospitalized
women delivered vaginally (85% and 73%, respectively), as shown
in Table 5. Among the 45 outpatient women who had delivered,
only three of their neonates required immediate resuscitation.
Moreover, only one of the 45 neonates of the outpatient women
for whom data were available was admitted to the neonatal ICU.
In contrast, most of the severe outcome ICU-admitted women
were delivered by cesarean section (20 of 33) with a median
Table 1. Characteristics of pregnant or postpartum women with 2009 A/H1N1v influenza infection.
ICU patients
(severe) (n=40)
Hospitalized non-severe
patients (moderate)
(n=111)
Outpatients
(mild) (n=164) p value
Age, years
,20 5 (13) 3 (3) 2 (1)
20–34 28 (70) 89 (80) 131 (80) 0.001
$35 7 (18) 19 (17) 31 (19)
Median age [min-max] 28 [17–45] 28 [15–43] 28 [14–45] NS
Pregnancy trimester
1
st trimester 3 (8) 0 (0) 33 (20)
2
nd trimester 9 (23) 24 (22) 76 (46) ,0.001
3
rd trimester and postpartum 28 (70) 87 (78) 55 (34)
Chronic pre-existing disease 23 (58) 32 (29) 44 (27) ,0.001
Obesity (BMI.30) 6 17 16 NS
Respiratory disease * 11 11 9 ,0.001
Cardiac or vascular disease 3 1 5 NS
Metabolic disease other than diabetes** 1 2 6 NS
Diabetes except gestational diabetes 1 1 2 NS
Neurologic disease 1 2 5 NS
Renal disease 0 0 2 NS
Hepatic disease 1 0 1 NS
Hematologic disease 2 1 3 NS
Immunosuppression 1 1 1 NS
Pregnancy-related disorders 3 (8) 12 (11) 11 (7) NS
Gestational diabetes 1 10 9 NS
Preeclampsia 1 0 2 NS
Others 2 2 0 NS
Chronic medication (pre- or intra-pregnancy) 13 (33) 11 (10) 18 (11) ,0.001
Corticosteroids 0 2 1 NS
Immunosuppression 0 0 1 NS
Others *** 13 9 17 ,0.001
Values: N (%) unless stated otherwise. NS: non-significant.
*includes asthma, restrictive syndrome.
**includes thyroid and adrenal insufficiency.
***includes bronchodilators, insulin, salicylic acid, fractionated heparin, L-thyroxin, antihypertensive agents.
doi:10.1371/journal.pone.0013112.t001
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20) were directly related to influenza illness. These cesarean
sections were mainly emergent procedures for both fetal
indications and critical maternal hypoxemia (9 of 17). In two
patients, the cesarean section was performed only for fetal
indications (non-reassuring fetal heart rate), and in six patients,
it was performed only to improve maternal oxygenation. In two
patients, the cesarean section was performed in the ICU because
of severe refractory hypoxemia that was incompatible with transfer
to an operating room.
Half of the neonates of women admitted to the ICU for whom
data were available were admitted to the NICU, as shown in
Table 5. Among the three maternal deaths, one had delivered a
healthy full-term neonate at term by cesarean section (indicated
because of thrombotic microangiopathy) before the ICU admis-
sion, one experienced an intra-uterine fetal death at 21 weeks of
gestation, and the third delivered at 34 weeks of gestation by
cesarean section to improve maternal oxygenation and for fetus
salvation. This infant was admitted to the neonatal ICU due to
prematurity and low Apgar scores (5 at 1 minute, 7 at 5 minutes)
and had survived at the time of NICU discharge. Data collection
for definitive neonatal morbidity and mortality is still in progress,
but to date, no cases of A/H1N1v influenza have been reported in
neonates.
Discussion
These are the first reported results of the largest cohort of
pregnant or postpartum women with confirmed 2009 A/H1N1v
influenza, including severe, moderate, and mild outcomes of the
disease, in a European country involved in the flu outbreak at the
end of 2009.
Several comments are raised by this study. First, the present
results confirm the data reported for past pandemics [1–4], which
indicate an increased risk for pregnant and/or postpartum woman
in developing a severe outcome of pneumonia and/or ARDS
during pandemic flu. Earlier in the spring and summer of 2009,
similar observations from the USA, Mexico, Canada, Australia,
and New Zealand were published, with pregnant or postpartum
patients accounting for 8 to 10% of H1N1-related critically ill
patients and 2 to 4% of deaths, whereas child-bearing-aged
women in these countries represent roughly 1% of the population
Table 2. Influenza symptoms, clinical course, and treatments of pregnant or postpartum women with 2009 A/H1N1v influenza.
ICU patients (severe)
(n=40)
Hospitalized non severe patients
(moderate) (n=111)
Outpatients (mild)
(n=164) p value
Symptoms*
Hyperthermia .37.8uC 34 (85) 97 (89) 131 (85) NS
Cough 28 (70) 93 (85) 134 (86) 0.04
Muscle aches 14 (35) 56 (51) 94 (61) 0.01
Headache 5 (13) 44 (40) 61 (39) 0.004
Rhinorrhea 3 (8) 34 (31) 51 (33) 0.006
Sore throat 2 (5) 14 (13) 19 (12) NS
Shortness of breath 31 (78) 22 (20) 14 (9) ,0.001
Vomiting 6 (15) 14 (13) 10 (6) NS
Diarrhea 1 (3) 1 (1) 3 (2) NS
Antiviral treatment 40 (100) 109 (98) 150 (91) 0.01
#2 days 18 (45) 87 (80) 132 (88)
3-5 days 10 (25) 16 (15) 13 (9) ,0.001
.5 days 12 (30) 6 (6) 5 (3)
Initial antibiotic therapy 32 (80) 75 (68) 65 (40) ,0.001
Hospitalization ward
Obstetric ward NA 94 (85) NA -
Medical ward NA 17 (15) NA -
Specific obstetric care*
,** 23/39 (59) 11/109 (10) 0/155 (0) ,0.001
Corticosteroids (fetal pulmonary maturation) 10 (26) 4 (4) 0 (0) ,0.001
Tocolysis 0 (0) 8 (7) 0 (0) 0.005
Artificial induction of labor 1 (3) 1 (1) 0 (0) NS
Cesarean section 17 (44) 1 (1) 0 (0) ,0.001
Fetal consequences*
,** 14/39 (36) 4/109 (4) 0/155 (0) ,0.001
Prematurity (,37 weeks of gestation) 13 (33) 2 (2) 0 (0) ,0.001
Miscarriage 0 (0) 1 (1) 0 (0) NS
Stillbirth 1 (3) 1 (1) 0 (0) NS
Values: N (%). NA: not applicable, NS: non-significant.
*Some data were only available for 109 non-severe hospitalized patients and 155 outpatients on March 31
st, 2010.
**Information about obstetric care or fetal consequences is directly related to H1N1 illness. Obstetric care and fetal consequences were registered for only the 39 ICU-
hospitalized women with a prepartum onset of influenza symptoms and excluding the only post-partum case in the registry.
doi:10.1371/journal.pone.0013112.t002
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again constituted a significant risk factor for severe illness during
the 2009 pandemic flu. Interestingly, Hanslik et al. measured the
risk for admission into an intensive care unit for a pregnant
woman and found an odds ratio of 5 [95% CI 4.0–6.9] [17].
Second, and in contrast with the above-mentioned experience
from the 2009 pandemic influenza in other countries [7,9,18–20],
pregnancy did not seem to significantly increase mortality in our
country. The R3G registry indeed recorded only three deaths in
France in pregnant or postpartum patients, and this finding was
confirmed by the InVS. In the work by Hanslik, heart failure,
obesity, and diabetes, but not pregnancy, were significantly
associated with death in France [17]. Interestingly, very recent
data from other countries in Asia, although comprising a smaller
series and from a single center, seemed to demonstrate the same
trend [21]. It is tempting to hypothesize that such an observation
could be partially to the following factors: (i) first, patient
characteristics (less obesity or coexisting diseases in our population
and in our patients in comparison with other series). Comparisons
of the incidence of co-existing illness between our cohort and the
American and Australian ones [18–20] revealed a lower incidence
of obesity (12% versus 20 to 42%) and asthma (9% versus 12 to
20%); (ii) second, early diagnosis and a shorter delay until the
initiation of antiviral treatment in our study, retrospectively
validating the French guidelines; (iii) third, very good compliance
of the physicians and patients; (iv) fourth, an increased awareness
of the specific severity of pandemic flu during pregnancy arising
from international experience.
When comparing non-severe with severe outcomes of pandemic
flu in French pregnant or postpartum women in the registry, the
main results were as follows: i) a lower incidence of coexisting
illnesses (28% compared with 58%), mainly respiratory disease,
and ii) a significantly shorter delay between the onset of disease
and initiation of oseltamivir treatment. Evidence for the benefit of
oseltamivir in preventing influenza complications remains insuf-
ficient to date [22], yet suggested by our series and those from the
USA or Australia [18–20]. In April 2010, the Centers for Disease
Control and Prevention (CDC) reported on 788 pregnant women
in the United States with 2009 A/H1N1v influenza with symptom
onset from April through August 2009 [23]. Among these patients,
early antiviral treatment appeared to be associated with fewer
admissions to an ICU and fewer deaths, although this result was
not adjusted for coexisting illnesses or the pregnancy trimester.
Our series confirmed that a delay in oseltamivir treatment after the
onset of symptoms constituted an independent risk factor
associated with the development of more severe outcomes of
2009 A/H1N1v influenza in pregnant women. We hypothesize
that earlier treatment with oseltamivir may also reflect easier
access to care and more informed physicians, which may have
allowed for prompt recognition of the most severe patients, thus
reducing subsequent severe morbidity or mortality due to better
triage and care.
Finally, the obstetric and neonatal consequences of pandemic
f l uo b s e r v e di nF r a n c ea p p e a r e dt ob er a t h e rl i m i t e d .C o n s i s t e n t
with the first reports from Victoria in Australia [19], New York
[20], and California [9], the 2009 A/H1N1v influenza illness
significantly increased the need for cesarean section delivery,
mainly due to worsening maternal conditions. Cesarean section
did not seem to worsen maternal conditions, because only one of
the 17 women died with critical hypoxemia. Intensive manage-
ment for maternal hypoxia, including extracorporeal membrane
oxygenation, also led to better than expected outcomes when
compared with the usual 30 to 35% mortality rate reported for
ARDS. The NICU admission rate also increased, mainly
Table 3. ICU-hospitalized severe patients (n=40).
Post-partum admission to the ICU 10 (25)
Median time from symptom onset to
ICU admission – days [min-max]
3 [0–17]
ICU indication(s):
Respiratory failure { 38 (95)
Cardiac failure 9 (23)
Neurologic failure 0 (0)
Renal failure { 1 (3)
Decompensation of an underlying pathology ¥ 3 (8)
Other * 1 (3)
Median SAPS II score on admission [min-max] 22 [6–74]
Median admission SOFA score [min-max] 2 [0–13]
Pathological admission pulmonary imaging # 32 (80)
Documented secondary pulmonary infection" 10 (25)
Ultimate respiratory failure:
None 1 (3)
Moderate hypoxemia 15 (38)
Acute lung injury (200,PaO2/FiO2,300) 5 (13)
Acute respiratory distress syndrome (PaO2/FiO2,200) 19 (48)
Cardiac failure during hospitalization in the ICU e 17 (43)
Neurologic failure during hospitalization in the ICU {{ 5 (13)
Renal failure during hospitalization in the ICU 6 (15)
Ultimate respiratory care:
Oxygen therapy 15 (38)
Non-invasive ventilation 5 (13)
Mechanical ventilation (with or without ECMO) 20 (50)
ECMO 11 (28)
Median duration of ECMO – days [min-max] 8 [4–38]
Other treatments:
Corticosteroids 12 (30)
Catecholamines 14 (35)
Renal replacement therapy 5 (13)
Transfusion 12 (30)
Other ** 1 (3)
Median length of ventilation, days [min-max] 13 [2–55]
Median ICU length of stay, days [min-max] 10 [2–80]
Death 3 (8)
Values: N (%) unless stated otherwise.
{Respiratory failure included moderate hypoxemia (in fourteen cases), acute
lung injury with 200,PaO2/FiO2,300 (in eight cases), acute respiratory
distress syndrome (in thirteen cases), severe dyspnea without hypoxemia (in
one case), and asthma crisis (in two cases).
{Thrombotic microangiopathy.
¥Homozygous sickle cell anemia and vaso-occlusive crisis with acute chest
syndrome (in one case), asthma (in one case), mitral stenosis and pulmonary
edema (in one case).
*Other included postpartum hemorrhage.
#Pathological pulmonaryimaging including interstitialsyndrome(innineteencases),
alveolar syndrome (in twenty-eight cases), and pleural effusion (in two cases).
"Secondary pulmonary infection included Streptococcus pneumoniae (in three cases)
and Streptococcus sp., E. coli, Pseudomonas, Haemophilus, Klebsiella pneumoniae,
Cytomegalovirus,a n dAspergillus fumigatus infections (in one case each).
eCardiac failure included cardiac dysfunction (in eight cases), vasoplegia (in
eight cases), short cardiac arrest (in two cases), and pericarditis (in four cases).
{{Neurologic failure included ischemic cerebro-vascular disease (in one case),
critical illness neuromyopathy (in two cases), hallucinations (in one case), and
psychomotor agitation (in one case).
**Other included immunoglobulins for the treatment of thrombotic microangiopathy.
doi:10.1371/journal.pone.0013112.t003
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fetuses from the most severely ill pregnant women. In contrast, a
worrisome observation from Australia and the USA reporting
increased neonatal morbidity and mortality did not seem to
occur in our cohort [19,20]. Severe neonatal morbidity and
mortality have remained extremely low (2 stillbirths and 2
neonatal deaths). These data are very important because they
were collected from a large series of infants (146) delivered by
mothers who had been treated with oseltamivir, thereby
reinforcing very recent data on the safety of this antiviral drug
during pregnancy [24].
One important limitation of this study was the lack of exhaustive
documentation of non-severe outcomes of pregnant women who
suffered from the 2009 pandemic flu in France. However, we did
include 275 patients with non-severe outcomes of pandemic flu
during pregnancy, which is the most important to our knowledge
in Europe to date. One may argue that a comparison of mostly
severe patients and some non-severe patients, who were registered
Table 4. Impact of coexisting illnesses and the timing of antiviral treatment on admission to an intensive care unit.
Adjusted OR 95% CI p value
Coexisting illness 5.11 2.22–11.78 ,0.001
Delay of treatment ,3 days after symptom onset Reference - -
Delay of treatment 3–5 days after symptom onset 4.78 1.89–12.09 0.001
Delay of treatment .5 days after symptom onset 61.24 14.35–261.25 ,0.001
OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0013112.t004
Table 5. Perinatal outcome.
ICU patients (severe)
(n=33)
Hospitalized non-severe
patients (moderate) (n=66)
Outpatients (mild)
(n=47) p value
A. PREGNANCY OUTCOME
Vaginal delivery (live birth) 11 (33) 48 (73) 40 (85) ,0.001
Cesarean delivery (live birth) 20 (61) 16 (24) 5 (11) ,0.001
Intra-uterine fetal death 1 (3) 1 (2) 0 (0) NS
term – weeks of gestation 21 29 -
Miscarriage 1 (3) 1 (2) 1 (2) NS
term – weeks of gestation -2 3 1 8
Termination of pregnancy 0 (0) 0 (0) 1 (2) NS
median term – weeks of gestation [range] -- 1 0
B. NEONATAL OUTCOME*
Median gestational age – weeks
[min-max]
37 [27–41] 38 [24–41] 40 [29–42] ,0.001
, 29 weeks of gestation 2/31 (6) 1/64 (2) 0/45 (0)
29–31 weeks of gestation 3/31 (10) 0/64 (0) 1/45 (2)
32–36 weeks of gestation 9/31 (29) 8/64 (12) 2/45 (4)
$37 weeks of gestation 17/31 (55) 55/64 (86) 42/45 (93)
Median birth weight - grams
[min-max]
2780 [1215–4110] 3270 [550–4670] 3350 [1520–4380] 0.01
,1500 2/31 (6) 1/63 (2) 0 (0)
1500–2499 12/31 (39) 6/63 (10) 1/44 (2)
$2500 17/31 (55) 56/63 (89) 43/44(98)
Newborn resuscitation in the L&D unit 15/31 (48)
{,
¥ 8/61 (13) 3/45 (7) ,0.001
Admission to neonatal intensive care unit 14/31 (45) 4/61 (7) 1/45 (2) ,0.001
Neonatal death (in the L&D unit or
in the neonatal intensive care unit)
1/31 (3) 1/61 (2) 0/45 (0) NS
Values: N (%) unless stated otherwise.
L&D: labor and delivery.
NA: not applicable. NS: non-significant.
*vaginal or cesarean delivery.
{intubation in 10 cases, resuscitation in 2 cases.
¥Apgar ,4 at five minutes in 3 cases.
doi:10.1371/journal.pone.0013112.t005
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assume that the worst biases will cause the 275 non-severe
outcomes in the registry to become less mild or moderate
outcomes than were indeed the case in real life. Consequently,
significant differences between severe and non-severe patients in
the registry will likely be clinically significant when they are
applied to the entire population.
In conclusion, the French experience of the pandemic 2009 A/
H1N1v flu in pregnant women resulted in an increase in morbidity
and ICU management of some patients, mainly at-risk patients
who were likely diagnosed and/or treated too late. Maternal
mortality has remained low and was lower than that observed in
other comparable countries. Moreover, at least in France, the
obstetric outcome and neonatal mortality did not appear to be
seriously affected by the H1N1 outbreak. This result may be due
to wider access to care, directive guidelines, good compliance from
patients and physicians, and early diagnosis and treatment with
oseltamivir.
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